DVDouglas Andreas Valverde

Douglas Andreas Valverde

*This is an algorithmically generated author record based on publicly available information.

Douglas Andreas Valverde has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Forecasting the Epidemiology of Inflammatory Bowel Disease in Brazil: A Temporal Evolution from 2012 to 2035

    by Abel Botelho Quaresma, Eduard Brunet-Mas, Stephanie B. Coward, Aderson O.M.C. Damiao, Claudio S.R. Coy, Julia Gorospe, Adriano A. F. Hino, Lindsay Hracs, Daniela Oliveira Magro, Remo Panaccione, et al.

    Background & Aims: Brazil is undergoing a rapid epidemiologic transition in inflammatory bowel disease (IBD). We aimed to characterize the temporal evolution of IBD in Brazil from 2012 to 2025 and forecast its burden through 2035, positioning the country within a global four-stage model.Methods: This nationwide, population-based study utilized the DATASUS database via the TT Disease Explorer platform. We identified individuals with Crohn’s Disease (CD), Ulcerative Colitis (UC), and IBD-Unclassifiable (IBD-U) using validated ICD-10 codes from the public healthcare system. Temporal trends (Annual Average Percent Changes: AAPCs) and autoregressive integrated moving average (ARIMA) modeling was used to forecast incidence and prevalence.Results: A total of 337,539 IBD patients were identified. Between 2012 and 2025, IBD prevalence rose from 29·85 to 158·18 per 100,000 inhabitants and IBD incidence rose from 9·35 to 12·34 per 100,000 inhabitants. The UC:CD prevalence ratio increased from 1·53:1 to 2·1:1. Hotspots were concentrated in the South and Southeast regions. ARIMA models forecast that IBD prevalence will reach 264·4 per 100,000, while incidence is forecasted to rise to 22·72 per 100,000 by 2035.Conclusions: The incidence and prevalence in Brazil are rising significantly. By 2035, this escalating burden will necessitate a structural shift in the public healthcare systems toward longitudinal models of chronic care management.

  • Open Access

    Psoriasis in the Brazilian Public Health System: A Nationwide Analysis of Healthcare Utilization and Inequalities, 2014–2024

    by Suzieni Padoin Zuccolo De Bortoli, Anber Ancel Tanaka, Rafael Aguilar Magalhães, João Victor Gonçalves Aques, João Lucas Volc, Douglas Andreas Valverde, Valderilio Feijó Azevedo

    Background: Psoriasis (PsO) is a chronic inflammatory disease associated with substantial healthcare needs. In Brazil, nationwide evidence based on administrative data remains limited, particularly regarding healthcare utilization and inequalities in the public health system. Objectives: The objective was to analyze nationwide patterns of healthcare utilization and to explore potential regional and sociodemographic inequalities in access to care among patients with PsO within the Brazilian Unified Health System (SUS) from 2014 to 2024. Methods: This retrospective observational study used nationwide administrative data from DATASUS, the health information system of the Brazilian Unified Health System. Patients with at least one healthcare encounter coded with ICD-10 L40 between 2014 and 2024 were included. Sociodemographic characteristics, clinical subtypes, geographic distribution, and temporal trends in healthcare utilization were analyzed. Registered healthcare prevalence for 2024 was estimated. Results: A total of 54,950 unique patients were identified. Psoriasis vulgaris was the most frequent subtype (38.8%). Women accounted for 57.7% of cases, and the most represented age group was 46–60 years. Most patients were classified as White (52.7%) or mixed race (35.1%). Higher case concentrations were observed in the Southeast and Northeast, with higher healthcare prevalence in the Southeast and South. Healthcare encounters declined in 2020, followed by recovery through 2024, with regional variation in registered healthcare prevalence, highlighting persistent inequalities. Conclusions: This nationwide real-world study highlights patterns of healthcare utilization and regional inequalities in psoriasis care within Brazil’s public health system. Administrative data provide valuable insights to support health policy and resource allocation in universal healthcare settings.

  • Open Access

    Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study

    by Daniel Herchenhorn, Haonne Abboud, Vinicius Freire, Juliana Tarouquella, Fernando Sabino M Monteiro, Andre P Fay, João Luís Reis Freitas, Rana R. Mckay, Brent Rose, Gustavo F Carvalhal, et al.

    PURPOSE: The Brazilian Public Health System (BPHS) provides sole health coverage for approximately 77% of the population. Analyzing BPHS data enables nationwide assessment of epidemiology, treatment patterns, and costs for men with prostate cancer (PCa). METHODS: We conducted a retrospective, population-based cohort study using linked administrative data from the BPHS Database DATASUS for patients with PCa treated in the BPHS from January 1, 2008, to March 31, 2023. Variables include demographics, clinical features, stage, treatments, and health care utilization. The primary objective was to evaluate the impact of race on stage at diagnosis, treatment delivery, and treatment costs. RESULTS: A total of 670,205 patients with PCa were treated during the study period; 277,030 (41.4%) were White and 393,175 (58.6%) non-White. Mean age at diagnosis was 72.9 years (40-99). Approximately 56% were diagnosed with stage I-III disease (56.1% v 55.5%), and 21% with metastatic disease (19.7% v 21.2%), with non-White men more frequently presenting with advanced stage ( P < .001). White men more commonly received local therapy in stage I, whereas non-White men received local therapy more frequently in stage III ( P < .001). Among 125,759 men with stage IV disease who received systemic therapy, only 22,393 (17.8%) received docetaxel, while use of first-generation antiandrogens and estrogens remained high (25%). Total PCa-directed expenditures reached In$ 1.83 billion, with mean costs 16.2% higher for White patients than for non-White patients. CONCLUSION: In the BPHS, race was associated with more advanced stages at diagnosis and differences in treatment delivery. High rates of de novo metastatic disease, underuse of docetaxel, and persistent use of agents without survival benefit highlight urgent gaps in PCa care. These findings may guide PCa policy in Brazil and other low- and middle-income countries.


  • Population-based Real-World Adoption of Advanced Therapies for Ulcerative Colitis in Brazil: Trends and Regional Differences from a Nationwide Public Healthcare Database

    by Maria Paz Gimenez Villamil, Maria Victoria Bein, Douglas Andreas Valverde, Mariane Christina Savio, Rafaela Araújo Molteni Moretti, Thyago Proença de Moraes, Abel Botelho Quaresma, Paulo Gustavo Kotze

  • Open Access

    Optimizing the Systemic Treatment for Metastatic Castration-Resistant Prostate Cancer in Lower-Middle–Income Countries: A 7-Year Analysis of the Brazilian Public Health System

    by Fernando Sabino Marques Monteiro, Vinicius Carrera Souza, Karine Martins da Trindade, Adriano Gonçalves e Silva, Augusto Mota, Diogo Assed Bastos, Douglas Andreas Valverde, Haonne Soares Abboud, Daniel Herchenhorn, Andrey Soares

    PURPOSE: Prostate cancer is the most prevalent cancer in men worldwide. As new treatments become available, costs also increase, and patients from lower-middle-income countries do not have access to those treatments due to cost restriction and governmental approval. However, several non–survival-prolonging treatments (nspTx) continue to be offered to patients with metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: We gathered retrospective data from patients with mCRPC treated under the Brazilian Public Health System (BPHS) from 2017 to 2023. Our analysis concentrated on assessing the treatment plans, the median duration of treatment (mDoT), and the costs associated with these plans. The main aim of this study was to clarify the overall expenses, timing, and types of therapies provided to patients with mCRPC. RESULTS: A cohort of 38,851 patients with mCRPC showed a mDoT of 20.5 months and total castration-resistant treatment costs of $333,200,939 US dollars (USD). Among them, 31,430 (81%) received survival-prolonging treatments (spTx), while 7,421 (19%) were given nspTx. The spTx group had a mDoT of 19.8 months, with total spending of $269,892,761 USD and an average cost per patient of $8,587.11 USD. The nspTx group's mDoT was 20.5 months, costing $63,308,180 USD in total and $8,530.95 USD per patient. Exploratory analysis indicated that funds spent on nonsurvival treatments for one patient could cover generic cabazitaxel (20 mg/m 2 once every 21 days, six cycles) for approximately two patients with mCRPC. CONCLUSION: This long-term analysis of the BPHS treatment of mCRPC shows substantial spending on spTx and nspTx. Although most patients received recommended spTx, 19% received nspTx at similar costs. Results indicate the need for reforms to prioritize evidence-based treatments in resource-limited settings.


  • Open Access

    REGIONAL AND MULTIFACTORIAL PATTERNS OF INFLAMMATORY BOWEL DISEASE IN BRAZIL: A SYSTEMATIC ANALYSIS OF HOT SPOTS IN WESTERN SÃO PAULO AND PARANÁ

    by Abel Botelho Quaresma, Fabio V. Teixeira, Douglas A. Valverde, Adriano A. F. Hino, Aderson Omc Damião, Paulo Gustavo Kotze

    Background: Inflammatory Bowel Disease (IBD) is a complex condition influenced by interactions among genetic, environmental, immunological, and behavioral factors. The global rise in IBD, particularly in rapidly urbanizing countries like Brazil, reflects environmental transitions’ impact on disease patterns. Regional disparities in diagnostic coverage and environmental factors highlight IBD “hot spots”, particularly in Western São Paulo and Northwestern Paraná, which share similar socio-economic and environmental characteristics. This study systematically reviews these epidemiological patterns to address gaps and support public health policies. Methods: A systematic literature review adhering to PRISMA guidelines was conducted to assess Brazilian IBD epidemiology from 2006 to 2026. Data sources included PubMed, SciELO, and LILACS, with Boolean search strategies incorporating controlled vocabulary and free-text terms. Eligible studies provided primary epidemiological data on IBD incidence, prevalence, and associated risk factors. Hot spots were identified through geospatial analysis using Moran’s I index, supported by integrative conceptual models like Directed Acyclic Graphs (DAGs). Results: The review identified prominent IBD hot spots in Western São Paulo and Northwestern Paraná, characterized by shared urbanization (85%+), agro-industrial activity, and dietary transitions. These regions exhibit increased prevalence due to multifactorial mechanisms, such as genetic predisposition, Westernized diets, reduced environmental microbial exposure, and pesticide-related dysbiosis. However, diagnostic infrastructure disparities highlight underreporting in less developed regions, complicating nationwide comparisons. Conclusion: Western São Paulo and Northwestern Paraná form a continuous IBD hot spot influenced by urbanization, agro-industrial practices, and environmental exposures. Addressing these challenges requires integrated public health policies focusing on environmental regulation, nutritional education, and improved diagnostic access. Future longitudinal studies should assess gene-environment interactions and further explore underrepresented regions to enhance IBD management and prevention strategies in Brazil.

  • Open Access

    GENERATIVE AI TOWARDS A COMPARATIVE ANALYSIS OF HOSPITALIZATION RATES AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH INFLIXIMAB, VEDOLIZUMAB, AND TOFACITINIB IN THE PUBLIC HEALTHCARE SYSTEM IN BRAZIL: A NATIONWIDE STUDY

    by Douglas Andreas Valverde, Abel Botelho Quaresma, Maria Paz Gimenez Villamil, Thyago Proença de Moraes, Paulo Gustavo Kotze

    Objective: Ulcerative colitis (UC) is a chronic inflammatory bowel disease that requires advanced therapies, including infliximab, vedolizumab, and tofacitinib. Our aim is to understand the hospitalization rates and outcomes associated with these therapies in real-world scenarios, which is crucial for optimizing patient management and healthcare resource allocation. Methods: This nationwide retrospective observational study analyzed real-world data (RWD) from Brazil’s public healthcare system (SUS) between January 2021 and December 2023. Data on hospitalizations, length of stay, mortality, costs, and non-IBD-related hospital admissions were extracted and analyzed using the Techtrials TT Disease Explorer and TT RWE Generator, leveraging generative artificial intelligence (GenAI) for data integration and analysis. Results: A total of 1,313 patients required hospitalization, with 1,434 hospitalizations recorded. The hospitalization rate per 100 patients was highest for tofacitinib (262.5), followed by infliximab (212.88) and vedolizumab (191.67). Patients treated with infliximab had the shortest hospital stay (Median 3.0 days [0-68]) and lowest costs (Median 510.83 BRL [23.45 - 111,594.14]), whilst vedolizumab had the highest hospitalization costs. Surgical intervention rates were highest among tofacitinib users. Non-IBD-related hospitalizations suggested potential adverse drug events, including gastrointestinal disorders, infections, and anemia. Conclusion: This study represents the first AI-assisted RWE analysis of UC hospitalizations in Brazil. The findings highlight the varying hospitalization burdens across advanced therapies, with tofacitinib associated with higher hospitalization rates and infliximab linked to shorter hospital stays and lower costs. These insights can inform clinical decision-making and healthcare policy. Future studies should further explore AI’s role in optimizing RWE research and UC management.

  • Open Access

    Nefrectomias Realizadas no Brasil: há diferença entre o tempo de internação quando o procedimento é realizado pelo Cirurgião Geral ou Urologista?

    by Suelen Miná Valadares de Almeida Silva, Lucas Rossato Chrun, Juan Felipe Martins Filgueiras, Vital Burko Santos, Tiago Ormelez Ruani, Christiano Machado Filho, Eduardo Zanetti Bergamaschi, Bruno De Figueiredo Pimpão, Douglas Andreas Valverde Andreas Valverde, Mark Fernando Neumaier

    Introdução e objetivo: A nefrectomia, realizada para o tratamento de lesões e câncer renal, é uma cirurgia que demanda profundo conhecimento técnico, e, por isso, realizada por especialistas. O estudo teve como objetivo principal, avaliar o tempo de internação dos pacientes pós-nefrectomia, quando realizada pelo cirurgião geral e urologista no Brasil. Como objetivo secundário, foram avaliadas variáveis como idade média dos pacientes e tipo de nefrectomia. Método: Foram coletados dados do DATASUS de todas as nefrectomias realizadas no SUS entre janeiro de 2012 a dezembro de 2022 com o CID C64 (Câncer Renal). Estatísticas descritivas foram empregadas para resumir os dados, e análises comparativas foram realizadas para avaliar as diferenças nos resultados entre as técnicas de nefrectomia parcial, total e radical. Resultados: Entre 2012 e 2022, foram realizadas 15803 nefrectomias totais oncológicas, 7999 nefrectomias parciais oncológicas, 3890 nefrectomias totais e 1928 nefrectomias parciais. A idade média dos pacientes foi 59,21 anos (18 a 104 anos) e o tempo médio de internação foi 6,2 dias (0 a 313 dias). A análise multivariável revelou que a cirurgia realizada por um cirurgião geral, quando comparada com um urologista, implica em 0,5054 dias a mais de internação (p < 0.001). O aumento da complexidade do procedimento e da idade do paciente também associaram-se ao aumento do tempo de internação. Conclusão: O tipo de especialista - urologista ou cirurgião geral - tem efeito estatisticamente significativo no tempo de internação. Além disso, idade e tipo de cirurgia também estão independentemente relacionados ao tempo de internação.

  • Open Access

    Temporal Trends in Surgery and Hospitalization Rates for Crohn’s Disease in Brazil: A Population-Based Study

    by João Augusto dos Reis Guerra, Daniela Oliveira Magro, Claudio Saddy Rodrigues Coy, Douglas A Valverde, Emilia Sousa de Oliveira, Abel Botelho Quaresma, Paulo Gustavo Kotze

    Introduction: Biological therapy has transformed the natural course of inflammatory bowel disease, but there are still controversies regarding its potential to reduce surgical rates for Crohn’s disease (CD). This study, conducted with the support of the Brazilian National Healthcare System, aimed to analyze temporal trends in surgery and hospitalization rates among patients with CD and to correlate these data with the dispensing of azathioprine (AZA), infliximab (IFX), and adalimumab (ADA). Methodology: This retrospective observational study used data from the National Public Healthcare Department of Informatics through the TT Disease Explorer® platform from 2012 to 2022. Demographic data, medications used, and the prevalence of surgical procedures and hospitalizations associated with the International Classification of Diseases codes for CD were analyzed. Annual average percent changes (AAPCs) were calculated to assess temporal trends. Results: Between 2012 and 2022, there was a significant increase of 288.07% in the diagnoses of CD, rising from 27 551 to 106 917 cases. Concurrently, there was an increase in the absolute number of patients treated with AZA, IFX, and ADA, with increasing rates of 65.79%, 251.09%, and 242.48%, respectively. However, the proportion of patients receiving AZA per CD patients decreased by 57.28%, from 44.79% to 19.13% (AAPC = −7.94%, 95% CI, −8.05 to −7.83; P < .001). The use of IFX remained relatively stable, with a slight change from 13.82% to 12.50% (AAPC = 0.01%, 95% CI, −0.20 to 0.22; P = .935), while the use of ADA decreased by 11.75%, from 11.65% to 10.28% (AAPC = −1.74%, 95% CI, −2.48 to −1.82; P < .001). The absolute number of hospitalizations related to CD increased by 57.71%. Despite the rise in the number of cases and the greater availability of biological treatments, the proportion of hospitalized patients decreased by 59.29%, from 6.19% to 2.52% (AAPC = −7.04%, 95% CI, −7.42 to −6.66; P < .001). Similarly, the proportion of surgical procedures relative to the total number of cases decreased by 55.08%, from 1.09% to 0.49% (AAPC = −5.73%, 95% CI, −6.68 to −4.77; P < .001). Conclusions: Despite the cumulative increase in the prevalence of CD cases in the country and the absolute increase in the dispensing of biologics, the proportion of hospitalizations and surgical procedures among CD patients treated in the public health system in Brazil decreased.


  • Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries

    by Fernando Sabino Marques Monteiro, Andre Deeke Sasse, Denizar Vianna Araujo, Rana R. McKay, Karine Martins da Trindade, Andrey Soares, João Ricardo Alves, Douglas Andreas Valverde, Diogo Assed Bastos, Nicholas D. James, et al.

    PURPOSE: The Brazilian Public Health System (BPHS) serves approximately 71,730 patients with prostate cancer (PC) every year for which androgen deprivation therapy (ADT) is the primary treatment for patients with advanced hormone-sensitive prostate cancer (aHSPC). Androgen receptor pathway inhibitors (ARPIs) are not accessible through the BPHS. Using the BPHS as a model, this study assesses the long-term economic effect of surgical versus medical castration in aHSPC treatment to strategize cost reduction and the incorporation of ARPI in developing countries. PATIENTS AND METHODS: Data of patients with aHSPC (ie, TxN1M0 ineligible for local treatment or TxNxM1) from the BPHS database were analyzed from January 1, 2011, to December 31, 2021, using the TECHTRIALS artificial intelligence platform. The main outcomes were quantitative and descriptive analyses as well as a cost analysis of surgical versus chemical castration. RESULTS: Of the 274,519 patients with aHSPC who received active treatment during the 11-year study period, 90% (n = 246,683) underwent chemical castration and 10% (n = 27,836) underwent bilateral subcapsular orchiectomy (BSO). The median duration of chemical castration was 28 months. The BPHS spent an estimated total of $665,552,091.40 US dollars (USD) on chemical castration and $5,939,348.47 USD on BSO, respectively. The cost per patient was $2,698 USD and $213.37 USD for chemical castration and BSO, respectively. Hypothetically, if all patients with aHSPC had undergone BSO, the total direct cost for the BPHS would have been $42,774,832.20 USD, saving $622,777,259.20 USD over 11 years, making it possible to offer low-dose abiraterone to 65% of aHSPC patients. CONCLUSION: On the basis of this extensive financial analysis from the world's largest public health system database, BSO appears to be a valuable alternative to chemical castration for treating aHSPC. In resource-limited environments, the cost savings from using BSO may allow access to drugs that will improve survival such as ARPIs.